Caldera Therapeutics
Cambridge
About Caldera Therapeutics
Caldera was founded in 2025 to advance innovative biologics in IBD, assembling a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits. Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $112.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2026)
- Website: calderatx.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/caldera-therapeutics-29258 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.